Preoperative adjuvant therapy is generally required for 6-8 weeks for patients with locally advanced gastric cancer without distant metastases, and can be extended appropriately for those with T4aN2 or T4b, but should not exceed 10 weeks. These preliminary designs are derived from the common time points for achieving optimal outcomes after treatment for advanced gastric cancer, but clinical validation is needed to determine whether this is truly the optimal time. All treated patients must undergo timely imaging or pathological efficacy evaluation, which is recommended every 4-6 weeks and should not exceed 6 weeks interval, in order to keep track of the patient’s response to treatment, adjust the treatment strategy at any time, and avoid unnecessary overtreatment. Patients with effective treatment should decide the timing of surgery according to the stage and the degree of response to treatment. Patients should not be given continuous radiotherapy because it is effective, but should be operated as early as possible and in time if the goal has been achieved, and neoadjuvant therapy should never exceed 3 months. Patients can generally recover within 3-6 weeks after radiotherapy, so the interval between treatment cessation and surgery should not be too long; if the patient’s general condition allows, about 3-4 weeks is preferable; especially for those who need pathological histological evaluation of the efficacy, and the treatment cycle is only 1-2 cycles, surgery can be considered at an interval of about 2 weeks, otherwise the accurate pathological efficacy may be affected.